Article Text

PDF
Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy
  1. Mio Hosokawa1,
  2. Fumio Shiraga1,
  3. Ayana Yamashita2,
  4. Chieko Shiragami2,
  5. Aoi Ono2,
  6. Yukari Shirakata2,
  7. Shuhei Kimura1,
  8. Yusuke Shiode1,
  9. Tetsuhiro Kawata1,
  10. Mika Hosogi1,
  11. Atsushi Fujiwara1,
  12. Yuki Morizane1
  1. 1Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
  2. 2Department of Ophthalmology, Kagawa University Faculty of Medicine, Kagawa, Japan
  1. Correspondence to Dr Mio Hosokawa, Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Mailing address: 2-5-1 Shikata-cho Kita-ku, Okayama City, Okayama 700-8558, Japan; hmo529{at}okayama-u.ac.jp

Abstract

Background This study aims to evaluate the therapeutic effect of intravitreal aflibercept injection for polypoidal choroidal vasculopathy (PCV).

Methods Eighteen eyes of 17 consecutive patients with PCV received three consecutive monthly intravitreal injections of aflibercept and one additional injection 2 months later (four injections totally). All patients underwent eye examinations, which included best-corrected visual acuity (BCVA), fluorescein angiography, indocyanine green angiography, and optical coherence tomography. The primary endpoint of the study was the regression of polypoidal lesions. The secondary endpoints were BCVA, central retinal thickness (CRT) and changes in retinal exudation.

Results Six months after the first aflibercept injection, the polypoidal lesions were completely resolved in 14 eyes (77.7%) and partially resolved in 4 eyes (22.2%). Although branching choroidal vascular networks were still present in all eyes, retinal exudative changes had completely resolved in 17 eyes (94.4%), and the mean CRT decreased significantly from 407.2±100.1 µm to 229.1±57.2 µm (p<0.0001). BCVA (logarithm of the minimal angle of resolution, logMAR) improved significantly from 0.414±0.384 at baseline to 0.297±0.334 after 6 months (p=0.016).

Conclusions At 6 months, aflibercept monotherapy effectively reduced polyps, retinal exudation and CRT in patients with PCV.

  • Macula
  • Retina

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • At a glance
    Keith Barton James Chodosh Jost Jonas